Fintel reports that on April 8, 2025, HC Wainwright & Co. initiated coverage of VolitionRx (NYSEAM:VNRX) with a Buy ...

H.C. Wainwright raised the firm’s price target on Pacira (PCRX) to $65 from $48 and keeps a Buy rating on the shares. The firm believes the ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Fold Holdings (NasdaqCM:FLD) with a Buy ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

H.C. Wainwright analyst Yi Chen initiated coverage of VolitionRx (VNRX) with a Buy rating and $2.50 price target VolitionRx is a diagnostics ...

Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.31, a high ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy recommendation. As of April 2, 2025, the average one-year price target for ...

Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...